Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: Is it therapy-related?

Haematologica

Volumn 97, Issue 6, 2012, Pages 919-925

  Tang, Guilin ^a   Zuo, Zhuang ^a   Thomas, Deborah A ^a   Lin, Pei ^a   Liu, Dingsheng ^a   Hu, Ying ^a   Kantarjian, Hagop M ^a   Bueso Ramos, Carlos ^a   Jeffrey Medeiros, L ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytogenetics; Cytotoxic therapy; Overall survival; Precursor B acute lymphoblastic leukemia; Therapy related

Indexed keywords

ALKYLATING AGENT; CD135 ANTIGEN; CD15 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; GYRASE INHIBITOR; METHOTREXATE; RAS PROTEIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; BONE MARROW; CHROMOSOME 17; CHROMOSOME 5; CHROMOSOME 7; DIPLOIDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; RETROSPECTIVE STUDY; REVIEW;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOPOISOMERASE II INHIBITORS;

EID: 84862131285     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.057752     Document Type: Review

References (26)

1. Vardiman JW AD, Brunning RD, Larson RA, Matutes E, Baumann I, Thiele J. Therapyrelated myeloid neoplasms. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. Lyon, France: IARC Press, 2008.
2. Pagano L, Pulsoni A, Tosti ME, Annino L, Mele A, Camera A, et al. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol. 1999;106(4):1037-40.
3. Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia-a review of 101 cases. Ann Oncol. 2008;19(9):1634-8.
4. Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol. 2001;114(3):539-43.
5. Chen W, Wang E, Lu Y, Gaal KK, Huang Q. Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review. Am J Clin Pathol. 2010;133(1):75-82.
6. Ishizawa S, Slovak ML, Popplewell L, Bedell V, Wrede JE, Carter NH, et al. High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities. Leukemia. 2003;17(6):1091-5.
7. Borowitz MJ. Precursor lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Fourth ed. Lyon, France: IARC Press, 2008.
8. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880-9.
9. Jaso J, Thomas DA, Cunningham K, Jorgensen JL, Kantarjian HM, Medeiros LJ, et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer. 2011;117(17):4009-17.
10. In: Shaffer LG, Tommerup N, eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger, 2005.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1965;53:457-81.
12. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
13. Merlat A, Lai JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, et al. Therapyrelated myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia. 1999;13(2): 250-7.
14. Lovett BD, Lo Nigro L, Rappaport EF, Blair IA, Osheroff N, Zheng N, et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci USA. 2001;98(17):9802-7.
15. Hotfilder M, Rottgers S, Rosemann A, Schrauder A, Schrappe M, Pieters R, et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19-cells. Cancer Res. 2005;65(4):1442-9.
16. Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110(4):1112-5.
17. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788-801.
18. Heerema NA, Nachman JB, Sather HN, La MK, Hutchinson R, Lange BJ, et al. Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group. Leukemia. 2004;18(5):939-47.
19. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11(5):429-38.
20. Okamoto R, Ogawa S, Nowak D, Kawamata N, Akagi T, Kato M, et al. Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia. Haematologica. 2010; 95(9):1481-8.
21. Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006;43(2):126-33.
22. Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk M, Attar EC, et al. Acute myeloid leukemia and myelodysplastic syndromes following radiation therapy are similar to de novo disease and differ from other therapyrelated myeloid neoplasms. J Clin Oncol. 2012;in press.
23. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002;20(18):3878-84.
24. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92(4): 1165-71.
25. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18(1):120-5.
26. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7): 2137-45.